Safinamide (Xadago®) is a novel dual mechanism drug which has been approved in the EU and US as add-on treatment to levodopa in Parkinson's disease (PD) therapy. In addition to its selective and reversible monoamine oxidase B (MAO-B) inhibition, safinamide through use-dependent sodium channel blockade reduces overactive glutamatergic transmission in basal ganglia, which is believed to contribute to motor symptoms and complications including levodopa-induced dyskinesia (LID). The present study investigated the effects of safinamide on the development of LID in 6-hydroxydopamine (6-OHDA) lesioned rats, evaluating behavioural, molecular and neurochemical parameters associated with LID appearance. 6-OHDA lesioned rats were treated with either saline, levodopa (6 mg/Kg) or levodopa plus safinamide (15 mg/Kg) for 21 days. Abnormal involuntary movements, motor performance, molecular composition of the striatal glutamatergic synapse, glutamate and GABA release were analysed. 
In the striatum, safinamide prevented the rearrangement of the subunit composition of NMDA receptors and the levodopa-induced increase of glutamate release, associated with dyskinesia, without affecting the levodopa-stimulated motor performance and dyskinesia. Overall, these findings suggest that the striatal glutamate-modulating component of safinamide's activity may contribute to its clinical effects where its long-term use as levodopa add-on therapy, significantly improves motor function and ON time without troublesome dyskinesia.

Safinamide modulates striatal glutamatergic signalling in a rat model of levodopa-induced dyskinesia / F. Gardoni, M. Morari, J. Kulisevsky, A. Brugnoli, S. Novello, C.A. Pisano, C. Caccia, M. Mellone, E. Melloni, G. Padoani, V. Sosti, S. Vailati, C. Keywood. - In: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. - ISSN 0022-3565. - 367:3(2018 Dec 01), pp. 442-451. [10.1124/jpet.118.251645]

Safinamide modulates striatal glutamatergic signalling in a rat model of levodopa-induced dyskinesia

F. Gardoni
Primo
;
M. Mellone;
2018

Abstract

Safinamide (Xadago®) is a novel dual mechanism drug which has been approved in the EU and US as add-on treatment to levodopa in Parkinson's disease (PD) therapy. In addition to its selective and reversible monoamine oxidase B (MAO-B) inhibition, safinamide through use-dependent sodium channel blockade reduces overactive glutamatergic transmission in basal ganglia, which is believed to contribute to motor symptoms and complications including levodopa-induced dyskinesia (LID). The present study investigated the effects of safinamide on the development of LID in 6-hydroxydopamine (6-OHDA) lesioned rats, evaluating behavioural, molecular and neurochemical parameters associated with LID appearance. 6-OHDA lesioned rats were treated with either saline, levodopa (6 mg/Kg) or levodopa plus safinamide (15 mg/Kg) for 21 days. Abnormal involuntary movements, motor performance, molecular composition of the striatal glutamatergic synapse, glutamate and GABA release were analysed. 
In the striatum, safinamide prevented the rearrangement of the subunit composition of NMDA receptors and the levodopa-induced increase of glutamate release, associated with dyskinesia, without affecting the levodopa-stimulated motor performance and dyskinesia. Overall, these findings suggest that the striatal glutamate-modulating component of safinamide's activity may contribute to its clinical effects where its long-term use as levodopa add-on therapy, significantly improves motor function and ON time without troublesome dyskinesia.
GABA; N-methyl-D-aspartate (NMDA); Parkinson's Disease; dopamine; glutamate
Settore BIO/14 - Farmacologia
1-dic-2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
442.full.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.13 MB
Formato Adobe PDF
1.13 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/596942
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 20
social impact